1. Home
  2. MIRM vs MGIC Comparison

MIRM vs MGIC Comparison

Compare MIRM & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$69.90

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo Magic Software Enterprises Ltd.

MGIC

Magic Software Enterprises Ltd.

HOLD

Current Price

$26.71

Market Cap

990.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
MGIC
Founded
2018
1983
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
990.3M
IPO Year
2019
1991

Fundamental Metrics

Financial Performance
Metric
MIRM
MGIC
Price
$69.90
$26.71
Analyst Decision
Strong Buy
Buy
Analyst Count
11
2
Target Price
$88.36
$18.00
AVG Volume (30 Days)
624.0K
43.4K
Earning Date
11-04-2025
11-18-2025
Dividend Yield
N/A
2.25%
EPS Growth
N/A
16.15
EPS
N/A
0.81
Revenue
$471,794,000.00
$603,216,000.00
Revenue This Year
$53.78
$12.87
Revenue Next Year
$19.91
$6.23
P/E Ratio
N/A
$33.01
Revenue Growth
53.66
12.65
52 Week Low
$36.88
$11.36
52 Week High
$78.55
$27.44

Technical Indicators

Market Signals
Indicator
MIRM
MGIC
Relative Strength Index (RSI) 54.42 66.83
Support Level $63.23 $26.61
Resistance Level $66.77 $27.44
Average True Range (ATR) 3.11 0.65
MACD 0.14 0.09
Stochastic Oscillator 62.10 77.15

Price Performance

Historical Comparison
MIRM
MGIC

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About MGIC Magic Software Enterprises Ltd.

Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.

Share on Social Networks: